ID   M3K7_HUMAN              Reviewed;         606 AA.
AC   O43318; B2RE27; E1P523; O43317; O43319; Q5TDN2; Q5TDN3; Q5TDT7;
AC   Q9NTR3; Q9NZ70;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   10-MAY-2017, entry version 190.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 7;
DE            EC=2.7.11.25 {ECO:0000269|PubMed:10094049, ECO:0000269|PubMed:10838074, ECO:0000269|PubMed:12589052};
DE   AltName: Full=Transforming growth factor-beta-activated kinase 1;
DE            Short=TGF-beta-activated kinase 1;
GN   Name=MAP3K7; Synonyms=TAK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A; 1B AND 1C).
RC   TISSUE=Lung;
RX   PubMed=9480845; DOI=10.1006/bbrc.1998.8124;
RA   Sakurai H., Shigemori N., Hasegawa K., Sugita T.;
RT   "TGF-beta-activated kinase 1 stimulates NF-kappa B activation by an
RT   NF-kappa B-inducing kinase-independent mechanism.";
RL   Biochem. Biophys. Res. Commun. 243:545-549(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1D), AND TISSUE SPECIFICITY.
RX   PubMed=11118615; DOI=10.1016/S0167-4781(00)00258-X;
RA   Dempsey C.E., Sakurai H., Sugita T., Guesdon F.;
RT   "Alternative splicing and gene structure of the transforming growth
RT   factor beta-activated kinase 1.";
RL   Biochim. Biophys. Acta 1517:46-52(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1A).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1A).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF MAP2K3/MKK3 AND MAP2K6/MKK6.
RX   PubMed=8663074; DOI=10.1074/jbc.271.23.13675;
RA   Moriguchi T., Kuroyanagi N., Yamaguchi K., Gotoh Y., Irie K., Kano T.,
RA   Shirakabe K., Muro Y., Shibuya H., Matsumoto K., Nishida E.,
RA   Hagiwara M.;
RT   "A novel kinase cascade mediated by mitogen-activated protein kinase
RT   kinase 6 and MKK3.";
RL   J. Biol. Chem. 271:13675-13679(1996).
RN   [9]
RP   INTERACTION WITH TAB1/MAP3K7IP1.
RX   PubMed=8638164; DOI=10.1126/science.272.5265.1179;
RA   Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y.,
RA   Ueno N., Irie K., Nishida E., Matsumoto K.;
RT   "TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal
RT   transduction.";
RL   Science 272:1179-1182(1996).
RN   [10]
RP   ENZYME REGULATION, AND FUNCTION.
RX   PubMed=9079627; DOI=10.1074/jbc.272.13.8141;
RA   Shirakabe K., Yamaguchi K., Shibuya H., Irie K., Matsuda S.,
RA   Moriguchi T., Gotoh Y., Matsumoto K., Nishida E.;
RT   "TAK1 mediates the ceramide signaling to stress-activated protein
RT   kinase/c-Jun N-terminal kinase.";
RL   J. Biol. Chem. 272:8141-8144(1997).
RN   [11]
RP   INTERACTION WITH TRAF6 AND TAB1/MAP3K7IP1, FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=10094049; DOI=10.1038/18465;
RA   Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z.,
RA   Matsumoto K.;
RT   "The kinase TAK1 can activate the NIK-I kappaB as well as the MAP
RT   kinase cascade in the IL-1 signalling pathway.";
RL   Nature 398:252-256(1999).
RN   [12]
RP   INTERACTION WITH TAB1, PHOSPHORYLATION AT THR-184; THR-187 AND
RP   SER-192, ACTIVATION, AND CATALYTIC ACTIVITY.
RX   PubMed=10838074; DOI=10.1016/S0014-5793(00)01588-X;
RA   Sakurai H., Miyoshi H., Mizukami J., Sugita T.;
RT   "Phosphorylation-dependent activation of TAK1 mitogen-activated
RT   protein kinase kinase kinase by TAB1.";
RL   FEBS Lett. 474:141-145(2000).
RN   [13]
RP   PHOSPHORYLATION AT SER-192, AND ENZYME REGULATION.
RX   PubMed=10702308; DOI=10.1074/jbc.275.10.7359;
RA   Kishimoto K., Matsumoto K., Ninomiya-Tsuji J.;
RT   "TAK1 mitogen-activated protein kinase kinase kinase is activated by
RT   autophosphorylation within its activation loop.";
RL   J. Biol. Chem. 275:7359-7364(2000).
RN   [14]
RP   DEPHOSPHORYLATION BY PPM1B/PP2CB, AND INTERACTION WITH PPM1B/PP2CB.
RX   PubMed=11104763; DOI=10.1074/jbc.M007773200;
RA   Hanada M., Ninomiya-Tsuji J., Komaki K., Ohnishi M., Katsura K.,
RA   Kanamaru R., Matsumoto K., Tamura S.;
RT   "Regulation of the TAK1 signaling pathway by protein phosphatase 2C.";
RL   J. Biol. Chem. 276:5753-5759(2001).
RN   [15]
RP   UBIQUITINATION, FUNCTION, ENZYME REGULATION, INTERACTION WITH
RP   TAB1/MAP3K7IP2 AND TAB2/MAP3K7IP2, AND IDENTIFICATION IN THE TRIKA2
RP   COMPLEX.
RX   PubMed=11460167; DOI=10.1038/35085597;
RA   Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J.;
RT   "TAK1 is a ubiquitin-dependent kinase of MKK and IKK.";
RL   Nature 412:346-351(2001).
RN   [16]
RP   INTERACTION WITH IRAK; TAB1/MAP3K7IP1; TAB2/MAP3K7IP2 AND TRAF6,
RP   PHOSPHORYLATION, ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12242293; DOI=10.1128/MCB.22.20.7158-7167.2002;
RA   Jiang Z., Ninomiya-Tsuji J., Qian Y., Matsumoto K., Li X.;
RT   "Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-
RT   induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma
RT   membrane and activate TAK1 in the cytosol.";
RL   Mol. Cell. Biol. 22:7158-7167(2002).
RN   [17]
RP   INTERACTION WITH PELI1 AND PELI2.
RX   PubMed=12804775; DOI=10.1016/S0014-5793(03)00533-7;
RA   Jensen L.E., Whitehead A.S.;
RT   "Pellino2 activates the mitogen activated protein kinase pathway.";
RL   FEBS Lett. 545:199-202(2003).
RN   [18]
RP   INTERACTION WITH PELI3.
RX   PubMed=12874243; DOI=10.4049/jimmunol.171.3.1500;
RA   Jensen L.E., Whitehead A.S.;
RT   "Pellino3, a novel member of the Pellino protein family, promotes
RT   activation of c-Jun and Elk-1 and may act as a scaffolding protein.";
RL   J. Immunol. 171:1500-1506(2003).
RN   [19]
RP   FUNCTION, INTERACTION WITH SMAD7; MAP2K3 AND P38 KINASE, MUTAGENESIS
RP   OF LYS-63, AND CATALYTIC ACTIVITY.
RX   PubMed=12589052; DOI=10.1091/mbc.02-03-0037;
RA   Edlund S., Bu S., Schuster N., Aspenstroem P., Heuchel R.,
RA   Heldin N.E., ten Dijke P., Heldin C.H., Landstrom M.;
RT   "Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of
RT   prostate cancer cells involves Smad7-dependent activation of p38 by
RT   TGF-beta-activated kinase 1 and mitogen-activated protein kinase
RT   kinase 3.";
RL   Mol. Biol. Cell 14:529-544(2003).
RN   [20]
RP   INTERACTION WITH TAB3/MAP3K7IP3.
RX   PubMed=14670075; DOI=10.1042/BJ20031794;
RA   Cheung P.C., Nebreda A.R., Cohen P.;
RT   "TAB3, a new binding partner of the protein kinase TAK1.";
RL   Biochem. J. 378:27-34(2004).
RN   [21]
RP   INTERACTION WITH DAB2.
RX   PubMed=15894542; DOI=10.1074/jbc.M501150200;
RA   Hocevar B.A., Prunier C., Howe P.H.;
RT   "Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-
RT   stimulated fibronectin synthesis through TGFbeta-activated kinase 1
RT   and activation of the JNK pathway.";
RL   J. Biol. Chem. 280:25920-25927(2005).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [23]
RP   UBIQUITINATION, PHOSPHORYLATION AT THR-187 BY AUTOCATALYSIS, SUBUNIT,
RP   AND FUNCTION.
RX   PubMed=16845370; DOI=10.1038/sj.embor.7400754;
RA   Thiefes A., Wolf A., Doerrie A., Grassl G.A., Matsumoto K.,
RA   Autenrieth I., Bohn E., Sakurai H., Niedenthal R., Resch K.,
RA   Kracht M.;
RT   "The Yersinia enterocolitica effector YopP inhibits host cell
RT   signalling by inactivating the protein kinase TAK1 in the IL-1
RT   signalling pathway.";
RL   EMBO Rep. 7:838-844(2006).
RN   [24]
RP   FUNCTION, ENZYME REGULATION, AND INTERACTION WITH TAOK1 AND TAOK2.
RX   PubMed=16893890; DOI=10.1074/jbc.M603627200;
RA   Huangfu W.C., Omori E., Akira S., Matsumoto K., Ninomiya-Tsuji J.;
RT   "Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-
RT   mediated NF-kappaB activation: TAO2 regulates TAK1 pathways.";
RL   J. Biol. Chem. 281:28802-28810(2006).
RN   [25]
RP   INTERACTION WITH PP2A AND PPP6C, AND DEPHOSPHORYLATION AT THR-187 BY
RP   PP2A AND PPP6C.
RX   PubMed=17079228; DOI=10.1074/jbc.M608155200;
RA   Kajino T., Ren H., Iemura S., Natsume T., Stefansson B.,
RA   Brautigan D.L., Matsumoto K., Ninomiya-Tsuji J.;
RT   "Protein phosphatase 6 down-regulates TAK1 kinase activation in the
RT   IL-1 signaling pathway.";
RL   J. Biol. Chem. 281:39891-39896(2006).
RN   [26]
RP   INTERACTION WITH RBCK1.
RX   PubMed=17449468; DOI=10.1074/jbc.M701913200;
RA   Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P.,
RA   Zhang M., Chen D.Y., Zhai Z.H., Shu H.B.;
RT   "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-
RT   triggered NF-kappaB activation by targeting TAB2/3 for degradation.";
RL   J. Biol. Chem. 282:16776-16782(2007).
RN   [27]
RP   UBIQUITINATION, INTERACTION WITH CYLD, AND DEUBIQUITINATION BY CYLD.
RX   PubMed=17548520; DOI=10.1084/jem.20062694;
RA   Reiley W.W., Jin W., Lee A.J., Wright A., Wu X., Tewalt E.F.,
RA   Leonard T.O., Norbury C.C., Fitzpatrick L., Zhang M., Sun S.C.;
RT   "Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-
RT   dependent kinase Tak1 and prevents abnormal T cell responses.";
RL   J. Exp. Med. 204:1475-1485(2007).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [30]
RP   INTERACTION WITH TGFBR1.
RX   PubMed=18758450; DOI=10.1038/ncb1780;
RA   Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V.,
RA   Schuster N., Zhang S., Heldin C.H., Landstrom M.;
RT   "The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a
RT   receptor kinase-independent manner.";
RL   Nat. Cell Biol. 10:1199-1207(2008).
RN   [31]
RP   INTERACTION WITH VRK2.
RX   PubMed=18286207; DOI=10.1371/journal.pone.0001660;
RA   Blanco S., Sanz-Garcia M., Santos C.R., Lazo P.A.;
RT   "Modulation of interleukin-1 transcriptional response by the
RT   interaction between VRK2 and the JIP1 scaffold protein.";
RL   PLoS ONE 3:E1660-E1660(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389 AND SER-439, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [34]
RP   INTERACTION WITH WDR34.
RX   PubMed=19521662; DOI=10.1007/s00018-009-0059-6;
RA   Gao D., Wang R., Li B., Yang Y., Zhai Z., Chen D.Y.;
RT   "WDR34 is a novel TAK1-associated suppressor of the IL-1R/TLR3/TLR4-
RT   induced NF-kappaB activation pathway.";
RL   Cell. Mol. Life Sci. 66:2573-2584(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389 AND SER-439, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [36]
RP   INTERACTION WITH TAB2, AND PHOSPHORYLATION AT THR-187.
RX   PubMed=19675569; DOI=10.1038/nature08247;
RA   Xia Z.-P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., Zeng W.,
RA   Chen Z.J.;
RT   "Direct activation of protein kinases by unanchored polyubiquitin
RT   chains.";
RL   Nature 461:114-119(2009).
RN   [37]
RP   REVIEW ON ENZYME REGULATION.
RX   PubMed=17496917; DOI=10.1038/sj.onc.1210413;
RA   Adhikari A., Xu M., Chen Z.J.;
RT   "Ubiquitin-mediated activation of TAK1 and IKK.";
RL   Oncogene 26:3214-3226(2007).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389 AND SER-439, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [39]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=20060931; DOI=10.1016/j.biocel.2009.12.023;
RA   Landstrom M.;
RT   "The TAK1-TRAF6 signalling pathway.";
RL   Int. J. Biochem. Cell Biol. 42:585-589(2010).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [42]
RP   FUNCTION, INTERACTION WITH TRIM5, AND PHOSPHORYLATION AT THR-187.
RX   PubMed=21512573; DOI=10.1038/nature09976;
RA   Pertel T., Hausmann S., Morger D., Zueger S., Guerra J., Lascano J.,
RA   Reinhard C., Santoni F.A., Uchil P.D., Chatel L., Bisiaux A.,
RA   Albert M.L., Strambio-De-Castillia C., Mothes W., Pizzato M.,
RA   Gruetter M.G., Luban J.;
RT   "TRIM5 is an innate immune sensor for the retrovirus capsid lattice.";
RL   Nature 472:361-365(2011).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389 AND SER-439, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [44]
RP   UBIQUITINATION AT LYS-72.
RX   PubMed=22406003; DOI=10.1016/j.cellsig.2012.02.017;
RA   Fan Y., Shi Y., Liu S., Mao R., An L., Zhao Y., Zhang H., Zhang F.,
RA   Xu G., Qin J., Yang J.;
RT   "Lys48-linked TAK1 polyubiquitination at lysine-72 downregulates
RT   TNFalpha-induced NF-kappaB activation via mediating TAK1
RT   degradation.";
RL   Cell. Signal. 24:1381-1389(2012).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; SER-389; SER-439
RP   AND SER-455, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [47]
RP   INTERACTION WITH IFIT5.
RX   PubMed=26334375; DOI=10.1016/j.cellsig.2015.08.018;
RA   Zheng C., Zheng Z., Zhang Z., Meng J., Liu Y., Ke X., Hu Q., Wang H.;
RT   "IFIT5 positively regulates NF-kappaB signaling through synergizing
RT   the recruitment of IkappaB kinase (IKK) to TGF-beta-activated kinase 1
RT   (TAK1).";
RL   Cell. Signal. 27:2343-2354(2015).
RN   [48]
RP   INVOLVEMENT IN FMD2, VARIANTS FMD2 GLN-70; GLU-100; ARG-168 AND
RP   LEU-512, CHARACTERIZATION OF VARIANTS FMD2 LEU-512 AND ARG-168,
RP   SUBUNIT, AND MUTAGENESIS OF PRO-512.
RX   PubMed=27426733; DOI=10.1016/j.ajhg.2016.05.024;
RA   Wade E.M., Daniel P.B., Jenkins Z.A., McInerney-Leo A., Leo P.,
RA   Morgan T., Addor M.C., Ades L.C., Bertola D., Bohring A., Carter E.,
RA   Cho T.J., Duba H.C., Fletcher E., Kim C.A., Krakow D., Morava E.,
RA   Neuhann T., Superti-Furga A., Veenstra-Knol I., Wieczorek D.,
RA   Wilson L.C., Hennekam R.C., Sutherland-Smith A.J., Strom T.M.,
RA   Wilkie A.O., Brown M.A., Duncan E.L., Markie D.M., Robertson S.P.;
RT   "Mutations in MAP3K7 that alter the activity of the TAK1 signaling
RT   complex cause frontometaphyseal dysplasia.";
RL   Am. J. Hum. Genet. 99:392-406(2016).
RN   [49]
RP   INVOLVEMENT IN CSCF, AND VARIANTS CSCF VAL-50 DEL; CYS-110 AND
RP   ARG-241.
RX   PubMed=27426734; DOI=10.1016/j.ajhg.2016.06.005;
RA   Le Goff C., Rogers C., Le Goff W., Pinto G., Bonnet D., Chrabieh M.,
RA   Alibeu O., Nistchke P., Munnich A., Picard C., Cormier-Daire V.;
RT   "Heterozygous mutations in MAP3K7, encoding TGF-beta-activated kinase
RT   1, cause cardiospondylocarpofacial syndrome.";
RL   Am. J. Hum. Genet. 99:407-413(2016).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 31-328 IN COMPLEX WITH TAB1
RP   AND ADENOSINE.
RX   PubMed=16289117; DOI=10.1016/j.jmb.2005.09.098;
RA   Brown K., Vial S.C., Dedi N., Long J.M., Dunster N.J.,
RA   Cheetham G.M.T.;
RT   "Structural basis for the interaction of TAK1 kinase with its
RT   activating protein TAB1.";
RL   J. Mol. Biol. 354:1013-1020(2005).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. Plays an
CC       important role in the cascades of cellular responses evoked by
CC       changes in the environment. Mediates signal transduction of TRAF6,
CC       various cytokines including interleukin-1 (IL-1), transforming
CC       growth factor-beta (TGFB), TGFB-related factors like BMP2 and
CC       BMP4, toll-like receptors (TLR), tumor necrosis factor receptor
CC       CD40 and B-cell receptor (BCR). Ceramides are also able to
CC       activate MAP3K7/TAK1. Once activated, acts as an upstream
CC       activator of the MKK/JNK signal transduction cascade and the p38
CC       MAPK signal transduction cascade through the phosphorylation and
CC       activation of several MAP kinase kinases like MAP2K1/MEK1,
CC       MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn
CC       activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B
CC       kinase complex (IKK). Both p38 MAPK and JNK pathways control the
CC       transcription factors activator protein-1 (AP-1), while nuclear
CC       factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB
CC       and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-
CC       induced apoptosis. In osmotic stress signaling, plays a major role
CC       in the activation of MAPK8/JNK1, but not that of NF-kappa-B.
CC       Promotes TRIM5 capsid-specific restriction activity.
CC       {ECO:0000269|PubMed:10094049, ECO:0000269|PubMed:11460167,
CC       ECO:0000269|PubMed:12589052, ECO:0000269|PubMed:16845370,
CC       ECO:0000269|PubMed:16893890, ECO:0000269|PubMed:21512573,
CC       ECO:0000269|PubMed:8663074, ECO:0000269|PubMed:9079627}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:10094049, ECO:0000269|PubMed:10838074,
CC       ECO:0000269|PubMed:12589052}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by proinflammatory cytokines and in
CC       response to physical and chemical stresses, including osmotic
CC       stress, oxidative stress, arsenic and ultraviolet light
CC       irradiation. Activated by 'Lys-63'-linked polyubiquitination and
CC       by autophosphorylation. Association with TAB1/MAP3K7IP1 and
CC       TAB2/MAP3K7IP2 promotes activation through autophosphorylation,
CC       whereas PPM1B/PP2CB, PP2A and PPP6C dephosphorylation leads to
CC       inactivation. {ECO:0000269|PubMed:10702308,
CC       ECO:0000269|PubMed:11460167, ECO:0000269|PubMed:12242293,
CC       ECO:0000269|PubMed:16893890, ECO:0000269|PubMed:9079627}.
CC   -!- SUBUNIT: Can form homodimer (PubMed:27426733). Binds both upstream
CC       activators and downstream substrates in multimolecular complexes.
CC       Interacts with TAB1/MAP3K7IP1, TAB2/MAP3K7IP2 and TAB3/MAP3K7IP3
CC       (PubMed:10838074, PubMed:11460167, PubMed:12242293,
CC       PubMed:14670075, PubMed:16289117, PubMed:19675569,
CC       PubMed:8638164). Identified in the TRIKA2 complex composed of
CC       MAP3K7/TAK1, TAB1/MAP3K7IP1 and TAB2/MAP3K7IP2 (PubMed:11460167).
CC       Interacts with PPM1L and PPM1B/PP2CB (PubMed:11104763).
CC       Interaction with PP2A and PPP6C leads to its repressed activity
CC       (PubMed:17079228). Interacts with TRAF6 and TAB1/MAP3K7IP1; during
CC       IL-1 signaling (PubMed:10094049, PubMed:12242293). Interacts with
CC       TAOK1 and TAOK2; interaction with TAOK2 interferes with MAP3K7
CC       interaction with IKKA, thus preventing NF-kappa-B activation
CC       (PubMed:16893890). Interacts with WDR34 (via WD domains)
CC       (PubMed:19521662). Interacts with CYLD and RBCK1 (PubMed:17449468,
CC       PubMed:17548520). Interacts with TGFBR1; induces MAP3K7/TAK1
CC       activation by TRAF6 (PubMed:18758450). Interacts with MAPK8IP1 and
CC       SMAD6 (By similarity). Interacts with isoform 1 of VRK2
CC       (PubMed:18286207). Interacts with DAB2; the interaction is induced
CC       by TGF-beta stimulation and may mediate TGF-beta stimulated JNK
CC       activation (PubMed:15894542). Interacts with TRIM5
CC       (PubMed:21512573). Part of a complex containing ITCH, NDFIP1 and
CC       MAP3K7 (By similarity). Interacts with IFIT5; the interaction
CC       synergizes the recruitment of IKK to MAP3K7 and enhances IKK
CC       phosphorylation (PubMed:26334375). {ECO:0000250|UniProtKB:Q62073,
CC       ECO:0000269|PubMed:10094049, ECO:0000269|PubMed:10838074,
CC       ECO:0000269|PubMed:11104763, ECO:0000269|PubMed:11460167,
CC       ECO:0000269|PubMed:12242293, ECO:0000269|PubMed:12589052,
CC       ECO:0000269|PubMed:12804775, ECO:0000269|PubMed:12874243,
CC       ECO:0000269|PubMed:14670075, ECO:0000269|PubMed:15894542,
CC       ECO:0000269|PubMed:16289117, ECO:0000269|PubMed:16845370,
CC       ECO:0000269|PubMed:16893890, ECO:0000269|PubMed:17079228,
CC       ECO:0000269|PubMed:17449468, ECO:0000269|PubMed:17548520,
CC       ECO:0000269|PubMed:18286207, ECO:0000269|PubMed:18758450,
CC       ECO:0000269|PubMed:19521662, ECO:0000269|PubMed:19675569,
CC       ECO:0000269|PubMed:21512573, ECO:0000269|PubMed:26334375,
CC       ECO:0000269|PubMed:27426733, ECO:0000269|PubMed:8638164}.
CC   -!- INTERACTION:
CC       B5Z6S0:cagA (xeno); NbExp=4; IntAct=EBI-358684, EBI-7287204;
CC       Q16543:CDC37; NbExp=5; IntAct=EBI-358700, EBI-295634;
CC       P07900:HSP90AA1; NbExp=5; IntAct=EBI-358700, EBI-296047;
CC       O14733:MAP2K7; NbExp=3; IntAct=EBI-358684, EBI-492605;
CC       Q9UQF2:MAPK8IP1; NbExp=11; IntAct=EBI-358684, EBI-78404;
CC       Q9UBE8:NLK; NbExp=3; IntAct=EBI-358684, EBI-366978;
CC       O00743:PPP6C; NbExp=4; IntAct=EBI-358684, EBI-359751;
CC       P40763:STAT3; NbExp=4; IntAct=EBI-358684, EBI-518675;
CC       Q15750:TAB1; NbExp=3; IntAct=EBI-358700, EBI-358643;
CC       Q9NYJ8:TAB2; NbExp=5; IntAct=EBI-358684, EBI-358708;
CC       Q8N5C8:TAB3; NbExp=3; IntAct=EBI-358684, EBI-359964;
CC       Q9Y4K3:TRAF6; NbExp=2; IntAct=EBI-358684, EBI-359276;
CC       P0CG48:UBC; NbExp=4; IntAct=EBI-358684, EBI-3390054;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12242293}.
CC       Cell membrane {ECO:0000269|PubMed:12242293}; Peripheral membrane
CC       protein {ECO:0000269|PubMed:12242293}; Cytoplasmic side
CC       {ECO:0000269|PubMed:12242293}. Note=Although the majority of
CC       MAP3K7/TAK1 is found in the cytosol, when complexed with
CC       TAB1/MAP3K7IP1 and TAB2/MAP3K7IP2, it is also localized at the
CC       cell membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1B;
CC         IsoId=O43318-1; Sequence=Displayed;
CC       Name=1A;
CC         IsoId=O43318-2; Sequence=VSP_004886;
CC       Name=1C;
CC         IsoId=O43318-3; Sequence=VSP_004887, VSP_004888;
CC       Name=1D;
CC         IsoId=O43318-4; Sequence=VSP_004886, VSP_004887, VSP_004888;
CC   -!- TISSUE SPECIFICITY: Isoform 1A is the most abundant in ovary,
CC       skeletal muscle, spleen and blood mononuclear cells. Isoform 1B is
CC       highly expressed in brain, kidney and small intestine. Isoform 1C
CC       is the major form in prostate. Isoform 1D is the less abundant
CC       form. {ECO:0000269|PubMed:11118615}.
CC   -!- PTM: Association with TAB1/MAP3K7IP1 promotes autophosphorylation
CC       at Ser-192 and subsequent activation. Association with
CC       TAB2/MAP3K7IP2, itself associated with free unanchored Lys-63
CC       polyubiquitin chain, promotes autophosphorylation and subsequent
CC       activation of MAP3K7. Dephosphorylation at Ser-192 by PPM1B/PP2CB
CC       and at Thr-187 by PP2A and PPP6C leads to inactivation.
CC       {ECO:0000269|PubMed:10702308, ECO:0000269|PubMed:10838074,
CC       ECO:0000269|PubMed:16845370, ECO:0000269|PubMed:17548520,
CC       ECO:0000269|PubMed:19675569, ECO:0000269|PubMed:21512573}.
CC   -!- PTM: 'Lys-48'-linked polyubiquitination at Lys-72 is induced by
CC       TNFalpha, and leads to proteasomal degradation. Undergoes 'Lys-
CC       48'-linked polyubiquitination catalyzed by ITCH (By similarity).
CC       Requires 'Lys-63'-linked polyubiquitination for
CC       autophosphorylation and subsequent activation. 'Lys-63'-linked
CC       ubiquitination does not lead to proteasomal degradation.
CC       Deubiquitinated by CYLD, a protease that selectively cleaves 'Lys-
CC       63'-linked ubiquitin chains. Deubiquitinated by Y.enterocolitica
CC       YopP. {ECO:0000250|UniProtKB:Q62073, ECO:0000269|PubMed:17548520,
CC       ECO:0000269|PubMed:22406003}.
CC   -!- DISEASE: Frontometaphyseal dysplasia 2 (FMD2) [MIM:617137]: A form
CC       of frontometaphyseal dysplasia, a progressive sclerosing skeletal
CC       dysplasia affecting the long bones and skull. Characteristic
CC       features include supraorbital hyperostosis, cranial hyperostosis,
CC       undermodeling of the small bones, flared metaphyses, and digital
CC       anomalies. Extra-skeletal manifestations include hearing loss,
CC       cardiac malformations, and stenosis, particularly of the upper
CC       airway and urinary tract. FMD2 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:27426733}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiospondylocarpofacial syndrome (CSCF) [MIM:157800]: A
CC       syndrome characterized by growth retardation, dysmorphic facial
CC       features, brachydactyly with carpal-tarsal fusion and extensive
CC       posterior cervical vertebral synostosis, cardiac septal defects
CC       with valve dysplasia, and deafness with inner ear malformations.
CC       CSCF transmission pattern is consistent with autosomal dominant
CC       inheritance. {ECO:0000269|PubMed:27426734}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAP3K7ID454ch6q15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB009357; BAA25026.1; -; mRNA.
DR   EMBL; AB009356; BAA25025.1; -; mRNA.
DR   EMBL; AB009358; BAA25027.2; -; mRNA.
DR   EMBL; AF218074; AAF27652.1; -; mRNA.
DR   EMBL; DQ314875; ABC40734.1; -; Genomic_DNA.
DR   EMBL; AK315774; BAG38124.1; -; mRNA.
DR   EMBL; AL121964; CAI19609.1; -; Genomic_DNA.
DR   EMBL; AL121837; CAI19609.1; JOINED; Genomic_DNA.
DR   EMBL; AL121964; CAI19610.1; -; Genomic_DNA.
DR   EMBL; AL121837; CAI19610.1; JOINED; Genomic_DNA.
DR   EMBL; AL121964; CAI19611.1; -; Genomic_DNA.
DR   EMBL; AL121837; CAI19611.1; JOINED; Genomic_DNA.
DR   EMBL; AL121964; CAI19612.1; -; Genomic_DNA.
DR   EMBL; AL121837; CAI19612.1; JOINED; Genomic_DNA.
DR   EMBL; AL121837; CAI23530.1; -; Genomic_DNA.
DR   EMBL; AL121964; CAI23530.1; JOINED; Genomic_DNA.
DR   EMBL; AL121837; CAI23531.1; -; Genomic_DNA.
DR   EMBL; AL121964; CAI23531.1; JOINED; Genomic_DNA.
DR   EMBL; AL121837; CAI23532.1; -; Genomic_DNA.
DR   EMBL; AL121964; CAI23532.1; JOINED; Genomic_DNA.
DR   EMBL; AL121837; CAI23533.1; -; Genomic_DNA.
DR   EMBL; AL121964; CAI23533.1; JOINED; Genomic_DNA.
DR   EMBL; CH471051; EAW48525.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48526.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48527.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48529.1; -; Genomic_DNA.
DR   EMBL; BC017715; AAH17715.1; -; mRNA.
DR   CCDS; CCDS5027.1; -. [O43318-2]
DR   CCDS; CCDS5028.1; -. [O43318-1]
DR   CCDS; CCDS5029.1; -. [O43318-3]
DR   CCDS; CCDS5030.1; -. [O43318-4]
DR   PIR; JC5955; JC5955.
DR   PIR; JC5956; JC5956.
DR   RefSeq; NP_003179.1; NM_003188.3. [O43318-2]
DR   RefSeq; NP_663304.1; NM_145331.2. [O43318-1]
DR   RefSeq; NP_663305.1; NM_145332.2. [O43318-3]
DR   RefSeq; NP_663306.1; NM_145333.2. [O43318-4]
DR   UniGene; Hs.594838; -.
DR   PDB; 2EVA; X-ray; 2.00 A; A=31-412.
DR   PDB; 2YIY; X-ray; 2.49 A; A=31-303.
DR   PDB; 4GS6; X-ray; 2.20 A; A=31-303.
DR   PDB; 4L3P; X-ray; 2.68 A; A=31-303.
DR   PDB; 4L52; X-ray; 2.54 A; A=31-303.
DR   PDB; 4L53; X-ray; 2.55 A; A=31-303.
DR   PDB; 4O91; X-ray; 2.39 A; A=31-303.
DR   PDB; 5E7R; X-ray; 2.11 A; A=31-303.
DR   PDB; 5GJD; X-ray; 2.79 A; A=31-303.
DR   PDB; 5GJF; X-ray; 2.89 A; A=31-303.
DR   PDB; 5GJG; X-ray; 2.61 A; A=31-303.
DR   PDB; 5J7S; X-ray; 2.37 A; A=31-303.
DR   PDB; 5J8I; X-ray; 2.40 A; A=31-303.
DR   PDB; 5J9L; X-ray; 2.75 A; A=31-303.
DR   PDB; 5JGA; X-ray; 2.00 A; A=31-303.
DR   PDB; 5JGB; X-ray; 2.80 A; A=31-303.
DR   PDB; 5JGD; X-ray; 3.10 A; A=31-303.
DR   PDB; 5JH6; X-ray; 2.37 A; A=31-303.
DR   PDB; 5JK3; X-ray; 2.37 A; A=31-303.
DR   PDBsum; 2EVA; -.
DR   PDBsum; 2YIY; -.
DR   PDBsum; 4GS6; -.
DR   PDBsum; 4L3P; -.
DR   PDBsum; 4L52; -.
DR   PDBsum; 4L53; -.
DR   PDBsum; 4O91; -.
DR   PDBsum; 5E7R; -.
DR   PDBsum; 5GJD; -.
DR   PDBsum; 5GJF; -.
DR   PDBsum; 5GJG; -.
DR   PDBsum; 5J7S; -.
DR   PDBsum; 5J8I; -.
DR   PDBsum; 5J9L; -.
DR   PDBsum; 5JGA; -.
DR   PDBsum; 5JGB; -.
DR   PDBsum; 5JGD; -.
DR   PDBsum; 5JH6; -.
DR   PDBsum; 5JK3; -.
DR   ProteinModelPortal; O43318; -.
DR   SMR; O43318; -.
DR   BioGrid; 112748; 152.
DR   DIP; DIP-27523N; -.
DR   IntAct; O43318; 50.
DR   MINT; MINT-88554; -.
DR   STRING; 9606.ENSP00000358335; -.
DR   BindingDB; O43318; -.
DR   ChEMBL; CHEMBL5776; -.
DR   GuidetoPHARMACOLOGY; 2082; -.
DR   iPTMnet; O43318; -.
DR   PhosphoSitePlus; O43318; -.
DR   BioMuta; MAP3K7; -.
DR   EPD; O43318; -.
DR   MaxQB; O43318; -.
DR   PaxDb; O43318; -.
DR   PeptideAtlas; O43318; -.
DR   PRIDE; O43318; -.
DR   DNASU; 6885; -.
DR   Ensembl; ENST00000369325; ENSP00000358331; ENSG00000135341. [O43318-3]
DR   Ensembl; ENST00000369327; ENSP00000358333; ENSG00000135341. [O43318-4]
DR   Ensembl; ENST00000369329; ENSP00000358335; ENSG00000135341. [O43318-1]
DR   Ensembl; ENST00000369332; ENSP00000358338; ENSG00000135341. [O43318-2]
DR   GeneID; 6885; -.
DR   KEGG; hsa:6885; -.
DR   UCSC; uc003pnz.3; human. [O43318-1]
DR   CTD; 6885; -.
DR   DisGeNET; 6885; -.
DR   GeneCards; MAP3K7; -.
DR   HGNC; HGNC:6859; MAP3K7.
DR   HPA; HPA007633; -.
DR   MIM; 157800; phenotype.
DR   MIM; 602614; gene.
DR   MIM; 617137; phenotype.
DR   neXtProt; NX_O43318; -.
DR   OpenTargets; ENSG00000135341; -.
DR   PharmGKB; PA30603; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118807; -.
DR   HOGENOM; HOG000231735; -.
DR   HOVERGEN; HBG003485; -.
DR   InParanoid; O43318; -.
DR   KO; K04427; -.
DR   OMA; PARSHPW; -.
DR   OrthoDB; EOG091G03QO; -.
DR   PhylomeDB; O43318; -.
DR   TreeFam; TF105116; -.
DR   Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-937042; IRAK2 mediated activation of TAK1 complex.
DR   Reactome; R-HSA-937072; TRAF6 mediated induction of TAK1 complex.
DR   Reactome; R-HSA-975163; IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation.
DR   SignaLink; O43318; -.
DR   SIGNOR; O43318; -.
DR   ChiTaRS; MAP3K7; human.
DR   EvolutionaryTrace; O43318; -.
DR   GeneWiki; MAP3K7; -.
DR   GenomeRNAi; 6885; -.
DR   PRO; PR:O43318; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000135341; -.
DR   CleanEx; HS_MAP3K7; -.
DR   ExpressionAtlas; O43318; baseline and differential.
DR   Genevisible; O43318; HS.
DR   GO; GO:0005671; C:Ada2/Gcn5/Ada3 transcription activator complex; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0097110; F:scaffold protein binding; IDA:MGI.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; IMP:UniProtKB.
DR   GO; GO:0043276; P:anoikis; ISS:BHF-UCL.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:BHF-UCL.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IMP:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IDA:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; ISS:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:Reactome.
DR   GO; GO:0050870; P:positive regulation of T cell activation; IC:UniProtKB.
DR   GO; GO:0002726; P:positive regulation of T cell cytokine production; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017421; MAPKKK7.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR26392:SF88; PTHR26392:SF88; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF038168; MAPKKK7; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm; Disease mutation;
KW   Isopeptide bond; Kinase; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Stress response; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1    606       Mitogen-activated protein kinase kinase
FT                                kinase 7.
FT                                /FTId=PRO_0000086252.
FT   DOMAIN       36    291       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      42     50       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    300       Interaction with MAPK8IP1. {ECO:0000250}.
FT   COMPBIAS      8     14       Poly-Ser.
FT   ACT_SITE    156    156       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      63     63       ATP.
FT   MOD_RES     184    184       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10838074}.
FT   MOD_RES     187    187       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10838074,
FT                                ECO:0000269|PubMed:16845370,
FT                                ECO:0000269|PubMed:19675569,
FT                                ECO:0000269|PubMed:21512573}.
FT   MOD_RES     192    192       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10702308,
FT                                ECO:0000269|PubMed:10838074}.
FT   MOD_RES     367    367       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     389    389       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     439    439       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     455    455       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK     72     72       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:22406003}.
FT   VAR_SEQ     404    430       Missing (in isoform 1A and isoform 1D).
FT                                {ECO:0000303|PubMed:11118615,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9480845}.
FT                                /FTId=VSP_004886.
FT   VAR_SEQ     509    518       PLAPCPNSKE -> ARTSCRTGPG (in isoform 1C
FT                                and isoform 1D).
FT                                {ECO:0000303|PubMed:11118615,
FT                                ECO:0000303|PubMed:9480845}.
FT                                /FTId=VSP_004887.
FT   VAR_SEQ     519    606       Missing (in isoform 1C and isoform 1D).
FT                                {ECO:0000303|PubMed:11118615,
FT                                ECO:0000303|PubMed:9480845}.
FT                                /FTId=VSP_004888.
FT   VARIANT      50     50       Missing (in CSCF).
FT                                {ECO:0000269|PubMed:27426734}.
FT                                /FTId=VAR_077341.
FT   VARIANT      70     70       E -> Q (in FMD2).
FT                                {ECO:0000269|PubMed:27426733}.
FT                                /FTId=VAR_077342.
FT   VARIANT     100    100       V -> E (in FMD2).
FT                                {ECO:0000269|PubMed:27426733}.
FT                                /FTId=VAR_077343.
FT   VARIANT     110    110       G -> C (in CSCF).
FT                                {ECO:0000269|PubMed:27426734}.
FT                                /FTId=VAR_077344.
FT   VARIANT     168    168       G -> R (in FMD2; increases
FT                                autophosphorylation; no effect on MAPK
FT                                signaling; no effect on NF-kappa-B
FT                                signaling).
FT                                {ECO:0000269|PubMed:27426733}.
FT                                /FTId=VAR_077345.
FT   VARIANT     241    241       W -> R (in CSCF).
FT                                {ECO:0000269|PubMed:27426734}.
FT                                /FTId=VAR_077346.
FT   VARIANT     512    512       P -> L (in FMD2; does not affect
FT                                interaction with TAB2; does not affect
FT                                homodimerization; increases
FT                                autophosphorylation; increases MAPK
FT                                signaling; increases NF-kappa-B
FT                                signaling).
FT                                {ECO:0000269|PubMed:27426733}.
FT                                /FTId=VAR_077347.
FT   MUTAGEN      63     63       K->W: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:12589052}.
FT   MUTAGEN     512    512       P->R,A: Enhances autophosphorylation;
FT                                Alters MAPK signaling.
FT                                {ECO:0000269|PubMed:27426733}.
FT   HELIX        33     35       {ECO:0000244|PDB:2EVA}.
FT   STRAND       36     43       {ECO:0000244|PDB:2EVA}.
FT   STRAND       46     55       {ECO:0000244|PDB:2EVA}.
FT   STRAND       58     64       {ECO:0000244|PDB:2EVA}.
FT   HELIX        70     83       {ECO:0000244|PDB:2EVA}.
FT   STRAND       92     95       {ECO:0000244|PDB:2EVA}.
FT   TURN         97    100       {ECO:0000244|PDB:2EVA}.
FT   STRAND      101    105       {ECO:0000244|PDB:2EVA}.
FT   HELIX       112    117       {ECO:0000244|PDB:2EVA}.
FT   STRAND      119    123       {ECO:0000244|PDB:2EVA}.
FT   HELIX       127    145       {ECO:0000244|PDB:2EVA}.
FT   STRAND      148    150       {ECO:0000244|PDB:2EVA}.
FT   HELIX       159    161       {ECO:0000244|PDB:2EVA}.
FT   STRAND      162    165       {ECO:0000244|PDB:2EVA}.
FT   TURN        166    169       {ECO:0000244|PDB:2EVA}.
FT   STRAND      170    173       {ECO:0000244|PDB:2EVA}.
FT   HELIX       182    186       {ECO:0000244|PDB:5GJF}.
FT   HELIX       193    195       {ECO:0000244|PDB:5JGA}.
FT   HELIX       198    201       {ECO:0000244|PDB:2EVA}.
FT   HELIX       209    224       {ECO:0000244|PDB:2EVA}.
FT   TURN        228    232       {ECO:0000244|PDB:2EVA}.
FT   HELIX       236    244       {ECO:0000244|PDB:2EVA}.
FT   HELIX       257    266       {ECO:0000244|PDB:2EVA}.
FT   HELIX       271    273       {ECO:0000244|PDB:2EVA}.
FT   HELIX       277    287       {ECO:0000244|PDB:2EVA}.
FT   HELIX       288    290       {ECO:0000244|PDB:2EVA}.
FT   TURN        292    295       {ECO:0000244|PDB:5JGA}.
FT   STRAND      300    302       {ECO:0000244|PDB:5JGA}.
FT   HELIX       402    411       {ECO:0000244|PDB:2EVA}.
SQ   SEQUENCE   606 AA;  67196 MW;  3D8F8147CD174013 CRC64;
     MSTASAASSS SSSSAGEMIE APSQVLNFEE IDYKEIEVEE VVGRGAFGVV CKAKWRAKDV
     AIKQIESESE RKAFIVELRQ LSRVNHPNIV KLYGACLNPV CLVMEYAEGG SLYNVLHGAE
     PLPYYTAAHA MSWCLQCSQG VAYLHSMQPK ALIHRDLKPP NLLLVAGGTV LKICDFGTAC
     DIQTHMTNNK GSAAWMAPEV FEGSNYSEKC DVFSWGIILW EVITRRKPFD EIGGPAFRIM
     WAVHNGTRPP LIKNLPKPIE SLMTRCWSKD PSQRPSMEEI VKIMTHLMRY FPGADEPLQY
     PCQYSDEGQS NSATSTGSFM DIASTNTSNK SDTNMEQVPA TNDTIKRLES KLLKNQAKQQ
     SESGRLSLGA SRGSSVESLP PTSEGKRMSA DMSEIEARIA ATTAYSKPKR GHRKTASFGN
     ILDVPEIVIS GNGQPRRRSI QDLTVTGTEP GQVSSRSSSP SVRMITTSGP TSEKPTRSHP
     WTPDDSTDTN GSDNSIPMAY LTLDHQLQPL APCPNSKESM AVFEQHCKMA QEYMKVQTEI
     ALLLQRKQEL VAELDQDEKD QQNTSRLVQE HKKLLDENKS LSTYYQQCKK QLEVIRSQQQ
     KRQGTS
//
